Are KRAS/BRAF mutations potent prognostic and/or predictive biomarkers in colorectal cancers?

Anticancer Agents Med Chem · 2012 · PMC3343383 · PMID 22043994

Europe PMC DOI

hedged sentence

0.1500

closest p · 3.0× alpha

0.1500

boldest claim

The sentences

showed a trendp = 0.15not close (p > 0.1)

Furthermore, a recent retrospective analysis by De Roock et al., examined 579 patients with chemotherapy-refractory CRC who received cetuximab treatment, and revealed that patients with p.G13D-mutated tumors showed a trend toward a higher response rate than other KRAS -mutated tumors (6.3% versus 1.6%, p = 0.15).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.